Asthma, Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
To determine the accuracy of the Respimetrix flow-volume monitoring device in measuring the patient's inspiratory capacity as compared to gold-standard measurements of inspiratory capacity on pulmonary function testing. Accuracy will be assessed before and after (A) pulmonary function testing and before and after (B) the administration of an inhaled bronchodilator medication.
Detailed description
1. Specific Aim #1: Compare the performance of the flow-volume test device to standard pulmonary function measurements. The investigators hypothesize that measurements of inspiratory capacity with the Respimetrix test device will: A. Accurately measure the inspiratory capacity as assessed on standard pulmonary function tests, and will B. Correlate with other measures of pulmonary function including spirometry (vital capacity, forced expiratory volume in 1 second) and lung volumes (total lung capacity, functional residual capacity and residual volume). 2. Specific Aim #2: Examine the ability of the flow-volume test device to track changes in standard pulmonary function measurements after the administration of an inhaled bronchodilator. The investigators hypothesize that the Respimetrix test device will: A. Accurately measure changes in inspiratory capacity in response to a standard dose of a short acting inhaled beta-agonist (4 puffs albuterol), B. Correlate with immediate changes in pulmonary function parameters including spirometry (vital capacity, forced expiratory volume in 1 second) and lung volumes (total lung capacity, functional residual capacity and residual volume).
Interventions
DIAGNOSTIC_TESTRespimetrix flow-volume monitoring device
The Respimetrix flow-volume monitoring device is being tested to validate its ability to measure Inspiratory Capacity
Sponsors
Pulmonary Critical Care Associates of Baltimore
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients 18 years of age or older who are being seen in the pulmonary clinic including Asthma and Chronic Obstructive Pulmonary Disease (COPD) patients. * Patients must be willing and able to provide informed consent to participate in the study. * Patients must be able to use a metered dose inhaler.
Exclusion criteria
* Contraindication to inhaler use * Tracheostomy * Incapacitating disability that interferes with the use of the inhaler or execution of the protocol * Unable to understand informed consent (e.g., non-English speakers)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validation | 1 year | Validate the Respimetrix device as compared to pulmonary function test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Validation | 1 year | Validate Forced Vital Capacity, Forced expired volume in 1 sec, Total lung capacity and residual volume |
Countries
United States
Outcome results
None listed